Clinical Trials Logo

Clinical Trial Summary

Participants in the study will use mifepristone 50 mg once-a-week for one year as a contraceptive. With this, we want to confirm that the chances of getting pregnant while using this contraceptive are very small. We also want to demonstrate that the use of mifepristone is safe, and it does not lead to any severe health problems. We expect fewer side effects compared to other frequently used contraceptives with hormones. Mifepristone does not contain these hormones. It is important to know how people experience that use of one tablet a week.


Clinical Trial Description

Mifepristone 50 mg, a progesterone receptor modulator, is a proven safe emergency contraceptive and a promising new weekly contraceptive. As mifepristone does not contain estrogens or progestogens, we anticipate users will not experience the undesirable side effects and health risks of current hormonal contraceptives. Furthermore, pills are a highly desired formulation approach and a weekly regimen instead of daily administration will likely contribute to a high acceptability and adherence among users. Based on promising early stage clinical data, we expect the use of weekly mifepristone 50 mg as a contraceptive will be safe, effective, and acceptable. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06394999
Study type Interventional
Source Leiden University Medical Center
Contact Rebecca Gomperts, PhD
Phone +31652052561
Email r.gomperts@lumc.nl
Status Not yet recruiting
Phase Phase 3
Start date September 2024
Completion date September 2029

See also
  Status Clinical Trial Phase
Completed NCT00653016 - An Open-label, Multicentre Study on Preference and Satisfaction of Canadian Women for the Transdermal Contraceptive Patch vs. Previous Primary Contraceptive Method Phase 4
Completed NCT00511784 - Relative Risks for Non-fatal Venous Thromboembolism, Ischemic Stroke and Myocardial Infarction in Users of ORTHO EVRA(Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared to Levonorgestrel-containing Oral Contraceptives. N/A
Completed NCT00236769 - A Study of Efficacy and Safety With the Transdermal Contraceptive System. Phase 3
Active, not recruiting NCT03124160 - Compare Two Copper IUDs: Mona Lisa NT Cu380 Mini and ParaGard Phase 3
Completed NCT00709189 - Bioequivalence Study of the Oral Contraceptive Tablet Containing Norgestimate (NGM)/Ethinyl Estradiol (EE) With or Without Folic Acid in Healthy Women. Phase 1
Completed NCT00775086 - Bioequivalence Study of Patches With Different Equilibration Profiles Phase 1
Completed NCT00258063 - A Study to Evaluate the Exposure of Norelgestromin and Ethinyl Estradiol From Commercial Lots of EVRA (a Transdermal Contraceptive Patch Manufactured by LOHMANN Therapie-Systeme) and CILEST (an Oral Contraceptive) Phase 1
Recruiting NCT04143659 - A Study to Evaluate the PK and PD of IM or SQ Injections of Levonorgestrel Butanoate (LB) for Female Contraception Phase 1
Completed NCT00697307 - Bioequivalence Study of Patches With Different Release Profiles N/A
Completed NCT00261482 - Evaluation of Women's Experience With EVRA (Norelgestromin + Ethinyl Estradiol) Transdermal Contraceptive Patch Compared With Previous Methods of Contraception. Phase 4
Completed NCT01286948 - Prevention of Ovulation Achieved by Single Intra-vaginal Administration of Levogel as Compared to Oral LNG Phase 1
Completed NCT00236795 - A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Triphasil. Phase 3
Completed NCT01833793 - Descriptive, Prospective, Non-interventional Study (NIS) to Describe Mirena and Amenorrhea Related Acceptability in Contraception Indication in Medical Practice N/A
Recruiting NCT02257671 - Oral Contraceptives and Economic Behaviour N/A
Recruiting NCT03432416 - Study of Efficacy, Cycle Control, and Safety of a NES-E2 Contraceptive Vaginal Ring Phase 2
Completed NCT01178125 - A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy Phase 3
Completed NCT00254865 - A Comparative Pharmacokinetic Study of ORTHO EVRA (a Transdermal Contraceptive Patch) and CILEST (an Oral Contraceptive) in Healthy Female Volunteers Phase 1
Completed NCT00258076 - A Study to Evaluate the Hormone Exposure From Multiple Commercial Lots of ORTHO EVRA (a Transdermal Contraceptive Patch) Phase 1
Completed NCT00331071 - Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart Attacks N/A
Completed NCT00377988 - A Postmarketing Study of the Risk of Venous Thromboembolism (Blood Clots), Myocardial Infarction (Heart Attacks), and Stroke Among Women Using ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared With Women Who Take Oral Contraceptives for Birth Control N/A